Isomorphic Labs raises $5bn to take AI-designed drugs to trials
The DeepMind spin-off has raised $5 billion to move its AI-designed drug candidates towards clinical trials.
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind, has raised $5 billion. The money is meant to help it move its drug candidates into clinical trials, TechCrunch reported.
The Series C round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. The company did not disclose its valuation, although Bloomberg reported earlier this month that it was seeking funding at a $50 billion valuation.
Who is backing it
Existing investors also put in more money. They include Alphabet’s GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
The new round comes only months after a $2.1 billion Series B in May.
How the technology works
Isomorphic was spun out of DeepMind in 2021. Its drug-design engine uses several AI simulation models and builds on AlphaFold, DeepMind’s model for predicting the shape of proteins.
AlphaFold earned Demis Hassabis and John Jumper the Nobel Prize in chemistry. Hassabis, Isomorphic’s founder and CEO, has stepped down as head of DeepMind to focus on drug discovery and is now DeepMind’s chairman.
The company says it has seen “positive preclinical results” in cancer and immune-system research, meaning work done before any testing in people. It has partnerships with drugmakers Eli Lilly, Novartis and Johnson & Johnson.
The new funding will go into developing the drug-design engine further and expanding into more types of medicine.
Why it matters
Clinical trials are the big test for any AI-designed medicine. Early lab results are promising, but only trials in people show whether a drug is safe and works. A $5 billion war chest gives Isomorphic the room to find out.
Source: TechCrunch


